Claims
- 1. A polynucleotide encoding a polypeptide comprising the sequence FLDQVAFXV (Seq. ID No. 1), wherein X is any amino acid.
- 2. A polynucleotide encoding a polypeptide comprising the sequence FLFSWYAXV (Seq. ID No. 3), wherein X is any amino acid.
- 3. The complement of a polynucleotide of claim 1.
- 4. The complement of a polynucleotide of claim 2.
- 5. A gene delivery vehicle comprising a polynucleotide of any of claims 1 to 4.
- 6. The gene delivery vehicle of claim 5, wherein the vehicle is selected from the group consisting of a plasmid, a cosmid, a recombinant viral vector, and a liposome-containing vehicle.
- 7. The gene delivery vehicle of claim 5, wherein the recominant viral vector is a recombinant DNA viral vector or a recombinant RNA viral vector.
- 8. A host cell comprising a polynucleotide of any of claims 1 to 4.
- 9. A method of recombinantly producing a polynucleotide, comprising growing the host cell of claim 8 and isolating the polynucleotide produced thereby.
- 10. A composition comprising a polynucleotide of any of claims 1 to 4, and a carrier.
- 11. The composition of claim 10, wherein the carrier is a solid support.
- 12. The composition of claim 10, wherein the carrier is a pharmaceutically acceptable carrier.
- 13. A polypeptide comprising the sequence FLDQVAFXV (Seq. ID No. 1), wherein X is any amino acid.
- 14. A polypeptide comprising the sequence FLFSWYAXV (Seq. ID No. 3), wherein X is any amino acid.
- 15. A polypeptide that is preferentially recognized by gp100 specific cytotoxic T lymphocytes which comprises the polypeptide of claim 13.
- 16. A polypeptide that is preferentially recognized by gp 100 specific cytotoxic T lymphocytes which comprises the polypeptide of claim 14.
- 17. A method of recombinantly producing a polypeptide, comprising growing the host cell of claim 8 under conditions suitable for the transcription and translation of the polynucleotide and isolating the polypeptide produced thereby.
- 18. A composition comprising the polypeptide of claim 15 or 16 and a carrier.
- 19. The composition of claim 18, wherein the carrier is a solid support.
- 20. The composition of claim 19, wherein the carrier is a pharmaceutically acceptable carrier.
- 21. A host cell comprising the polypeptide of claim 15 or 16.
- 22. The host cell of claim 21, wherein the cell is an antigen presenting cell (APC)and the polypeptide is present on the surface of the cell.
- 23. The host cell of claim 22, wherein the APC is a dendritic cell.
- 24. A population of educated, antigen-specific immune effector cells produced by culturing naive immune effector cells with antigen-presenting cells (APC) cells which express the polypeptide of claim 14 or claim 15 on the surface of the APCs.
- 25. The population of claim 24, wherein the antigen presenting cells (APCs) are dendritic cells.
- 26. The population of claim 24, wherein the immune effector cells are cytotoxic T lymphocytes (CTLs).
- 27. The population of claim 24, wherein immune effector cells are genetically modified.
- 28. The population of claim 24, wherein the antigen-presenting cells are genetically modified.
- 29. A composition comprising the population of any of claims 24 to 28, and a carrier.
- 30. The composition of claim 29, wherein the carrier is a pharmaceutically acceptable carrier.
- 31. A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of the polypeptide of claim 15 or 16, under the conditions that induce an immune response to the polypeptide.
- 32. The method of claim 31, further comprising administering an effective amount of a cytokine to the subject.
- 33. The method of claim 31, further comprising administering an effective amount of a co-stimulatory molecule to the subject.
- 34. A method of inducing an immune response to a melanoma antigen in a subject, comprising administering to the subject an effective amount of the antigen-presenting cell of claim 22 and under conditions that induce an immune response to the antigen.
- 35. The method of claim 34, further comprising administering an effective amount of a cytokine to the subject.
- 36. The method of claim 34, further comprising administering an effective amount of a co-stimulatory molecule to the subject.
- 37. The method of claim 34, wherein the antigen-presenting cell is genetically modified.
- 38. The method of claim 37, further comprising genetically modifying the cell to express a cytokine.
- 39. The method of claim 37, further comprising genetically modifying the cell to express a co-stimulatory molecule.
- 40. A method of adoptive immunotherapy, comprising administering to a subject an effective amount of a population of educated, antigen-specific immune effector cells of any of claims 24 to 28.
- 41. A database comprising the the nucleotide sequence of any of the polynucleotides of claims 1 to 4.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority (under 35 U.S.C. §119(e)), ot provisional U.S. Application No. 60/103,229, filed Oct. 5, 1998, the contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60103229 |
Oct 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09249272 |
Feb 1999 |
US |
Child |
09920480 |
Aug 2001 |
US |